Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Is BRAF the Achilles' Heel of thyroid cancer?

× No keyword cloud information.

7 in total

1. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells.

Authors: Dingxie Liu; Zhi Liu; Stephen Condouris; Mingzhao Xing
Journal: J Clin Endocrinol Metab Date: 2007-03-20 Impact factor: 5.958

2. Mps1 is associated with the BRAF^V600E mutation but does not rely on the classic RAS/RAF/MEK/ERK signaling pathway in thyroid carcinoma.

Authors: Yike Li; Yanyan Zhang; Shuaishuai Xiao; Pengzhou Kong; Caixia Cheng; Ruyi Shi; Fang Wang; Ling Zhang; Juan Wang; Zhiwu Jia; Shuai Wu; Yun Liu; Jiansheng Guo; Xiaolong Cheng; Yongping Cui; Jing Liu
Journal: Oncol Lett Date: 2018-04-24 Impact factor: 2.967

3. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

Authors: Rebecca Leboeuf; Jacqueline E Baumgartner; Miriam Benezra; Roberta Malaguarnera; David Solit; Christine A Pratilas; Neal Rosen; Jeffrey A Knauf; James A Fagin
Journal: J Clin Endocrinol Metab Date: 2008-04-01 Impact factor: 5.958

Is BRAF the Achilles' Heel of thyroid cancer?

1. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells.

2. Mps1 is associated with the BRAF^V600E mutation but does not rely on the classic RAS/RAF/MEK/ERK signaling pathway in thyroid carcinoma.

3. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

Review 4. Thyroid carcinoma: molecular pathways and therapeutic targets.

Review 5. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

6. MYC is a metastasis gene for non-small-cell lung cancer.

7. The insulin and igf-I pathway in endocrine glands carcinogenesis.

Is BRAF the Achilles' Heel of thyroid cancer?

1. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells.

2. Mps1 is associated with the BRAFV600E mutation but does not rely on the classic RAS/RAF/MEK/ERK signaling pathway in thyroid carcinoma.

3. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

Review 4. Thyroid carcinoma: molecular pathways and therapeutic targets.

Review 5. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

6. MYC is a metastasis gene for non-small-cell lung cancer.

7. The insulin and igf-I pathway in endocrine glands carcinogenesis.

2. Mps1 is associated with the BRAF^V600E mutation but does not rely on the classic RAS/RAF/MEK/ERK signaling pathway in thyroid carcinoma.